|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
TRANSPLANTATION
From the Department of Stem Cell Biology, University of
Groningen and Division of Hematology, University Hospital Groningen,
Groningen, The Netherlands.
Low-toxicity conditioning regimens prior to bone marrow
transplantation (BMT) are widely explored. We developed a new protocol using hematopoietic growth factors prior to low-dose total body irradiation (TBI) in recipients of autologous transplants to establish high levels of long-term donor cell engraftment. We hypothesized that
treatment of recipient mice with growth factors would selectively deplete stem cells, resulting in successful long-term donor cell engraftment after transplantation. Recipient mice were treated for 1 or
7 days with growth factors (stem cell factor [SCF] plus interleukin
11 [IL-11], SCF plus Flt-3 ligand [FL], or granulocyte colony-stimulating factor [G-CSF]) prior to low-dose TBI (4 Gy). Donor cell chimerism was measured after transplantation of congenic bone marrow cells. High levels of donor cell engraftment were observed
in recipients pretreated for 7 days with SCF plus IL-11 or SCF plus FL.
Although 1-day pretreatments with these cytokines initially resulted in
reduced donor cell engraftment, a continuous increase in time was
observed, finally resulting in highly significantly increased levels of
donor cell contribution. In contrast, G-CSF treatment showed no
beneficial effects on long-term engraftment. In vitro stem cell assays
demonstrated the effect of cytokine treatment on stem cell numbers.
Donor cell engraftment and number of remaining recipient stem cells
after TBI were strongly inversely correlated, except for groups treated
for 1 day with SCF plus IL-11 or SCF plus FL. We conclude that
long-term donor cell engraftment can be strongly augmented by treatment
of recipient mice prior to low-dose TBI with hematopoietic growth
factors that act on primitive cells.
(Blood. 2002;100:312-317) Low-toxicity conditioning regimens are increasingly
applied in settings of allogeneic or autologous bone marrow
transplantation (BMT) for an expanding variety of clinical
applications.1-6 Especially for transplantation protocols
in gene therapy, or treatment of autoimmune diseases, a nonmyeloablated
bone marrow environment is desired for autologous stem cells to engraft
effectively.7-10 Most clinical transplantation protocols
still use high-dose conditioning regimens to prevent rejection of the
donor graft and to create a microenvironment in which transplanted
(stem) cells are able to migrate efficiently to the bone marrow and
"home" to appropriate niches.11-14 No unequivocal
vision on the mechanism of homing and engraftment exists and discussion
continues on whether conditioning prior to BMT leads to creating actual
"space" in the bone marrow microenvironment or whether competition
is induced between remaining recipient stem cells and infused donor
cells.15-19 A recent study of Ponomaryov et
al20 suggests that the up-regulation of stromal derived
factor-1 (SDF-1) in response to total body irradiation (TBI) is
important in the homing process, underscoring the role of humoral
factors produced by stromal cells. In addition, evidence has been
obtained that the cell cycle status of the transplanted cells plays
a significant role and can be manipulated with growth factor
treatment.21-24
We hypothesize that a strong depletion of the recipients'
hematopoietic system prior to BMT will lead to enhanced donor cell engraftment. Specifically, we questioned whether long-term donor cell
engraftment can be affected by pretreatment of transplant recipients
with various hematopoietic growth factors prior to low-dose TBI. This
concept is supported by data showing that chemotherapy (5-fluorouracil)
after growth factor treatment with stem cell factor (SCF) can result in
severe stem cell depletion.25,26 Apparently, growth factor
treatment induces stem cells to proliferate and increase their
sensitivity toward myeloablative treatment. We administered growth
factors affecting primitive stem cells (SCF plus interleukin-11
[IL-11] or SCF plus Flt-3 ligand [FL]) or progenitor cells
(granulocyte colony-stimulating factor [G-CSF]). Our results
demonstrate that long-term donor cell engraftment after low-dose TBI
can be strongly augmented by pretreatment of recipients with
hematopoietic growth factors acting on primitive cells.
Mice
Treatments
Two hours after growth factor treatment, mice received a single dose of
4 Gy sublethal TBI at a dose rate of 0.89 Gy/min, using a
137Cs Each group consisted of 9 to 11 mice; 3 were allocated for the cobblestone area-forming cell (CAFC) assay and the remaining animals were used as transplant recipients. Control mice, not treated with growth factors, were irradiated similarly. CAFC assay Growth factor administration in mice leads to migration of cells from bone marrow to spleen and liver.27-29 Because we wanted to assess the extent of stem cell depletion in recipients conditioned with TBI, we estimated the total number of stem cells before and after irradiation with CAFC assays on bone marrow, spleen, and liver cells, and calculated the percentage of surviving cells after irradiation. Bone marrow suspensions were obtained by flushing either 1 or 2 femurs of each mouse according to standard procedures. Spleen suspensions were acquired as described.29 Liver suspensions were obtained by dissecting and weighing the complete liver. A piece of about 10% was prepared and gently pressed through a stainless steel sieve after which liver cells were collected. Single cells were obtained by repeatedly flushing the liver cells through a 25-gauge needle. The remaining part of the liver was weighed again and the exact fraction of used liver material was calculated. Marrow, spleen, and liver cellularities were determined using a Coulter Counter (Coulter Electronics, Dunstable, United Kingdom) to calculate the appropriate cell numbers for the stem cell assays. Femur cellularity was assumed to represent 6% of total marrow cellularity.30,31 Each data point in the CAFC assay was obtained by pooling bone marrow, spleen, or liver suspensions of 3 mice. The total number of CAFCs per mouse was calculated by adding the CAFC number of bone marrow plus spleen plus liver.The CAFC assay, a limiting dilution in vitro assay to distinguish between different subsets of stem cells,32,33 was performed exactly as previously described.29 Transplantation and determination of peripheral blood cell chimerism Twenty-four hours after sublethal irradiation, female CD45.2 recipient mice received transplants of 3 × 106 freshly harvested unfractionated bone marrow cells from male CD45.1 donor mice by intravenous injection into the retro-orbital plexus. Peripheral blood cell chimerism in recipients was determined in 2 independent groups of mice (n = 3-4/group) by flow cytometry, at first every 2 weeks (up to week 12), and thereafter every 4 weeks until week 40. In short, 50 µL tail blood was drawn from each mouse and erythrocytes were eliminated by hypotonic lysis (0.16 M NH4Cl, 1.0 × 10 4 M EDTA, 0.017 M NaCl, 5 minutes at room
temperature). Leukocytes were washed and stained with donor-specific
anti-CD45.1 monoclonal antibody (mAb) conjugated with phycoerythrin
(PE) and either host-specific anti-CD45.2 labeled with fluorescein
isothiocyanate (FITC) or FITC-labeled anti-Gr-1, anti-B220, or
anti-CD8a (all mAbs from Pharmingen, San Diego, CA). Stained cells were
washed and resuspended in 200 µL phosphate-buffered saline plus 2%
fetal calf serum. Two-color analysis (FACSCalibur; Becton Dickinson,
Palo Alto, CA) was performed to determine the percentage of donor- and
host-derived leukocytes or donor B and T lymphocytes and granulocytes
to check for multilineage mixed chimerism.
Statistics Unpaired Student t tests were performed to determine significant differences between engraftment levels of growth factor-treated mice and untreated controls. The 95% confidence limits (CLs) were calculated for each CAFC subset. Nonoverlapping 95% CLs were interpreted as P < .05.
Stem cell numbers after growth factor administration before and after TBI To determine the effect of growth factor treatment on stem cell pools, we performed CAFC assays on bone marrow, spleen, and liver cells of mice treated for 1 or 7 days with SCF plus IL-11, SCF plus FL, or G-CSF. Table 1 provides an overview of the relative CAFC frequencies that were measured in bone marrow, spleen, and liver cells. Figure 1 demonstrates the corresponding total CAFC pool size in each organ and in the entire mouse. Figure 1A-C depicts the absolute numbers of CAFCs-day 7 (progenitor cells) per total mouse (ie, in bone marrow plus spleen plus liver). In 1-day growth factor-treated mice no significant expansion of progenitor cells was observed. Although the relative frequency of CAFCs-day 7 in mice treated with SCF plus IL-11 was higher than in control mice, the cellularity in the femur of these mice was lower (12 × 106/femur vs 22 × 106/femur). In contrast, after the 7-day growth factor treatments, progenitor cells expanded 3- to 4-fold and migrated from the bone marrow toward the liver and, in particular, the spleen. This effect was most notable with the combination of SCF plus IL-11.
Primitive stem cells (CAFCs-day 35) demonstrated a different pattern in response to growth factor treatment (Figure 1D-F). Treatment with SCF plus IL-11 or G-CSF for 1 day resulted in a 2.5- to 3-fold expansion of stem cells. Continuation of the growth factor treatment for an additional 6 days did not result in further expansion, but led to a significant shift of primitive cells toward the spleen (Table 1). In contrast, 1-day treatment with SCF plus FL did not result in an increased number of stem cells, but stem cells expanded about 4-fold after a 7-day treatment. Again, most cells resided in the spleen. To establish the radiosensitivity of progenitors and primitive stem
cells, we calculated the percentage of surviving cells 24 hours after
irradiation per total mouse (Figure 2).
Compared to TBI alone, 1 day of SCF plus IL-11 or SCF plus FL
pretreatment resulted in a 4-fold reduced radiosensitivity of
progenitor cells (CAFCs-day 7), whereas radiosensitivity of primitive
stem cells (CAFCs-day 35) was reduced 2.7-fold (Figure 2A). A short
G-CSF treatment did not significantly change the radiosensitivity of cells compared to controls. In contrast, after 7 days of growth factor
administration, both CAFC subsets were more severely depleted than in
mice conditioned with TBI alone (Figure 2B). Moreover, a 7-day growth
factor treatment led to a much more pronounced difference in
sensitivity between progenitors and stem cells. Whereas about 1% of
progenitor cells survived in the 7-day growth factor-treated
groups, almost complete depletion of primitive stem cells was
achieved in SCF plus FL and to a lesser extent in mice treated with SCF
plus IL-11. These findings indicate that a 7-day treatment with SCF in
combination with either IL-11 or FL results in a considerably increased
sensitivity of hematopoietic cells toward low-dose TBI.
Donor cell engraftment after BMT Recipient female mice received transplants of 3 × 106 unfractionated congenic bone marrow cells from male hosts after low-dose TBI. Subsequently, long-term donor cell engraftment was determined by fluorescence-activated cell-sorter (FACS) analysis of donor and recipient leukocyte contribution. Two independent experiments were performed and pooled data are shown in Figure 3. The transplantation was considered successful when stable or increasing donor cell engraftment was maintained from week 12 onward (Figure 3). In 85% of control mice (17 of 20, Figure 3A-C) chimerism was achieved, reaching values of 40% ± 4.1% (SEM) donor leukocytes. Seven-day treatment with SCF plus IL-11 showed rapid donor cell reconstitution, resulting in significantly higher levels compared to control mice from week 4 onward (n = 6, P < 1 × 108; Figure
3A). Although engraftment remained high throughout the study,
donor cell contribution dropped very gradually over time. Interestingly, donor cell engraftment in 1-day SCF plus IL-11-treated mice showed a completely opposite pattern. The first month after transplantation, a significantly lower donor cell engraftment was
observed (P < .02), which, however, was followed by a
slow, but steady increase. Sixteen weeks after BMT, donor leukocyte contribution was significantly higher than control values
(P < .05).
Figure 3B demonstrates donor cell engraftment in mice treated with SCF plus FL. Unlike 7-day, SCF-plus-IL-11-treated mice, chimerism in animals treated with SCF plus FL did not drop in the long-term. Almost full donor leukocyte chimerism (~90%) was reached (n = 7, P < .00001). Although a significantly lower engraftment was found in the 1-day SCF-plus-FL-treated group compared to controls up to 4 weeks after transplantation (P < .01), from week 12 onward donor leukocyte contribution was significantly higher than in controls (n = 8, P < .01). Similar to the 1-day SCF-plus-IL-11 group, engraftment slowly but continuously kept increasing during the course of the study, reaching similar levels as the 7-day SCF plus FL group at week 32 (P < .0001). It is apparent that 7-day G-CSF treatment prior to TBI had a different effect on donor cell engraftment after BMT than either SCF plus IL-11 or SCF plus FL (Figure 3C). Although increased donor cell levels (~70%) were initially observed, (n = 8, P < .00001), subsequently, 16 weeks after BMT, engraftment gradually decreased toward control values at 24 weeks after transplantation. Mice treated for 1 day with G-CSF initially engrafted equally well as control animals, but all 8 mice eventually showed a gradual decrease in engraftment. To ensure that a true multilineage mixed chimerism was established in all groups, we checked for donor B and T lymphocytes as well as granulocytes in all recipient mice 28 to 40 weeks after BMT, using anti-B220, anti-CD8a, and anti-Gr-1 antibodies. The contribution of total donor leukocytes, as shown in Figure 3, was proportionally reflected in all 3 lineages (data not shown). Stem cell depletion and long-term donor cell engraftment We hypothesized that for successful long-term donor cell engraftment after transplantation, depletion of recipient stem cells would be required. Thus, a relationship between the extent of depletion of host stem cells and levels of donor cell engraftment was predicted. In Figure 4 this relationship between residual recipient CAFCs-day 35 remaining after 4 Gy TBI and donor cell engraftment at 24 weeks after transplantation is shown. Evidently, in all 7-day growth factor-treated groups, the control group, and the 1-day G-CSF-treated group, a strong inverse correlation (R2 = 0.957) exists between long-term donor cell engraftment and surviving CAFCs-day 35 after TBI. Interestingly, although relatively many stem cells survived radiation after 1-day SCF plus IL-11 or 1-day SCF plus FL treatment, donor cell chimerism in these mice was very high.
In this study, we show that growth factor treatment of recipient mice prior to low-dose TBI can modulate donor cell engraftment levels after syngeneic BMT. This modulation is dependent on the particular growth factor or growth factor combination used, but it is also highly dependent on the duration of the growth factor treatment. Within 4 weeks after BMT donor cell engraftment in all mice pretreated for 7 days with either of the growth factor combinations was dramatically increased compared to engraftment in untreated mice. This high donor cell contribution remained stable for at least 4 months. Most pronouncedly, almost full donor chimerism (90%) was reached in the SCF plus FL group even after a 1-day treatment period. Also, after a short 1-day growth factor pretreatment with SCF plus IL-11, a highly significant increase in donor leukocyte contribution was seen, although this became apparent only several months after transplantation. These findings are in accordance with data that we have previously obtained by a 1-day treatment of recipient mice with SCF alone prior to low-dose TBI.34 Interestingly, a difference in donor cell engraftment was observed between mice treated with growth factors with an effect on primitive stem cells (SCF plus IL-11 or FL) and G-CSF, which primarily affects progenitors. Because it has been shown that G-CSF administered before chemotherapy enhanced stem cell damage,35,36 we expected that G-CSF would also sensitize the stem cell compartment toward TBI, resulting in higher donor leukocyte contribution after transplantation. However, although 1-day G-CSF-treated cells were equally sensitive toward low-dose TBI as controls, the absolute number of remaining CAFCs-day 35 after TBI was considerably higher than in controls. In agreement with our hypothesis on the correlation between percentage donor cell contribution and degree of stem cell depletion, donor cell engraftment was considerably lower in 1-day G-CSF-treated mice than in control mice and decreased gradually over time. Seven-day G-CSF treatment initially resulted in a high donor cell engraftment, but values dropped, as expected, toward controls several weeks after transplantation. Thus, the sensitizing effect of G-CSF was not observed. Mardiney and Malech37 showed that a 5-day G-CSF treatment prior to very low-dose TBI (1.6 Gy) and BMT led to significantly enhanced donor cell contribution in mice. However, they followed engraftment only up to 16 weeks after transplantation, whereas donor cell contribution in our experiment dropped toward control values only at 24 weeks after transplantation. In the majority of our growth factor-treated groups we observed that the degree of stem cell depletion indeed is strongly correlated with the degree of donor cell engraftment, as we predicted. However, we observed an unexpectedly high donor cell chimerism in mice pretreated for 1 day with SCF plus IL-11 or SCF plus FL. This high level of engraftment cannot be explained by enhanced depletion of recipient stem cells, because many CAFCs-day 35 remained after TBI. We speculate that as yet unknown microenvironmental changes in the complex bone marrow stromal system caused by growth factor administration prior to TBI may influence engraftment. Induction of mixed chimerism after allogeneic BMT in animals and in patients has been shown to cause increased immunocompetence, increased transplantation tolerance, reduced graft-versus-host disease, and reduced posttransplantation toxicity.2,38-40 Here, we were able to create almost full donor cell chimerism both short- and long-term after transplantation with male-into-female transplantations. It has been shown that engraftment can be slightly impaired after transplantation of male cells into mildly conditioned female recipients.41,42 In addition, it has been shown that the CD45.1 antigen, which is expressed by the congenic C57BL/6.SJL.Ptprca mice we used as donors, may be mildly immunogenic.43 Thus, our syngeneic, sex-mismatched transplantation model sets the stage for testing a similar approach in allogeneic transplantation settings. However, in these situations a growth factor pretreatment protocol may be combined with thymic irradiation or administration of antibodies causing a costimulatory blockade to obtain sufficient immune suppression.39,44,45
The authors would like to thank Geert Mesander for help with the FACS analyses and Dr Piet Wierenga for intravenous injection of bone marrow cells.
Submitted April 2, 2001; accepted February 12, 2002.
Supported by the Dutch Cancer Society, grant NKB1996-1204. G.d.H. is a fellow of the Royal Netherlands Academy of Arts and Sciences (KNAW).
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Gerald de Haan, Department of Stem Cell Biology, University of Groningen, A Deusinglaan 1, NL-9713 AV Groningen, The Netherlands; e-mail: g.de.haan{at}med.rug.nl.
1. Sykes M, Preffer F, McAfee S, et al. Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation. Lancet. 1999;353:1755-1759[CrossRef][Medline] [Order article via Infotrieve].
2.
Slavin S, Nagler A, Naparstek E, et al.
Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases.
Blood.
1998;91:756-763 3. Slavin S, Nagler A, Varadi G, Or R. Graft vs autoimmunity following allogeneic non-myeloablative blood stem cell transplantation in a patient with chronic myelogenous leukemia and severe systemic psoriasis and psoriatic polyarthritis. Exp Hematol. 2000;28:853-857[CrossRef][Medline] [Order article via Infotrieve].
4.
Slavin S, Nagler A.
Immunotherapy in conjunction with autologous and allogeneic blood or marrow transplantation in lymphoma.
Ann Oncol.
1998;9(suppl)1:31-39 5. Singhal S, Safdar A, Chiang KY, et al. Non-myeloablative allogeneic transplantation ("microallograft") for refractory myeloma after two preceding autografts: feasibility and efficacy in a patient with active aspergillosis. Bone Marrow Transplant. 2000;26:1231-1233[CrossRef][Medline] [Order article via Infotrieve]. 6. Gomez-Almaguer D, Ruiz-Arguelles GJ, Ruiz-Arguelles A, Gonzalez-Llano O, Cantu OE, Hernandez NE. Hematopoietic stem cell allografts using a non-myeloablative conditioning regimen can be safely performed on an outpatient basis: report of four cases. Bone Marrow Transplant. 2000;25:131-133[CrossRef][Medline] [Order article via Infotrieve].
7.
Rosenzweig M, MacVittie TJ, Harper D, et al.
Efficient and durable gene marking of hematopoietic progenitor cells in nonhuman primates after nonablative conditioning.
Blood.
1999;94:2271-2286 8. Maze R, Hanenberg H, Williams DA. Establishing chemoresistance in hematopoietic progenitor cells. Mol Med Today. 1997;3:350-358[CrossRef][Medline] [Order article via Infotrieve].
9.
James RI, Warlick CA, Diers MD, Gunther R, McIvor RS.
Mild preconditioning and low-level engraftment confer methotrexate resistance in mice transplanted with marrow expressing drug-resistant dihydrofolate reductase activity.
Blood.
2000;96:1334-1341 10. Snowden JA, Brooks PM, Biggs JC. Haemopoietic stem cell transplantation for autoimmune diseases. Br J Haematol. 1997;99:9-22[CrossRef][Medline] [Order article via Infotrieve]. 11. Moore MAS. Stem cell proliferation: Ex vivo and in vivo observations. Stem Cells. 1997;15:239-248[Medline] [Order article via Infotrieve]. 12. Hardy CL. The homing of hematopoietic stem cells to the bone marrow. Am J Med Sci. 1995;309:260-266[Medline] [Order article via Infotrieve].
13.
Szilvassy SJ, Bass MJ, Van Zant G, Grimes B.
Organ-selective homing defines engraftment kinetics of murine hematopoietic stem cells and is compromised by ex vivo expansion.
Blood.
1999;93:1557-1566 14. Cui JS, Wahl RL, Shen TL, et al. Bone marrow cell trafficking following intravenous administration. Br J Haematol. 1999;107:895-902[CrossRef][Medline] [Order article via Infotrieve].
15.
Stewart FM, Crittenden RB, Lowry PA, Pearson WS, Quesenberry PJ.
Long-term engraftment of normal and post-5-fluorouracil murine marrow into normal nonmyeloablated mice.
Blood.
1993;81:2566-2571
16.
Tomita Y, Sachs DH, Sykes M.
Myelosuppressive conditioning is required to achieve engraftment of pluripotent stem cells contained in moderate doses of syngeneic bone marrow.
Blood.
1994;83:939-948 17. Mauch P, Constine L, Greenberger J, et al. Hematopoietic stem cell compartment: acute and late effects of radiation therapy and chemotherapy. Int J Radiat Oncol Biol Phys. 1995;31:1319-1339[CrossRef][Medline] [Order article via Infotrieve].
18.
Stewart FM, Zhong S, Wuu J, Hsieh C, Nilsson SK, Quesenberry PJ.
Lymphohematopoietic engraftment in minimally myeloablated hosts.
Blood.
1998;91:3681-3687 19. Quesenberry PJ, Ramshaw H, Crittenden RB, et al. Engraftment of normal murine marrow into nonmyeloablated host mice. Blood Cells. 1994;20:348-350[Medline] [Order article via Infotrieve]. 20. Ponomaryov T, Peled A, Petit I, et al. Induction of the chemokine stromal-derived factor-1 following DNA damage improves human stem cell function. J Clin Invest. 2000;106:1331-1339[Medline] [Order article via Infotrieve].
21.
Yamaguchi M, Ikebuchi K, Hirayama F, et al.
Different adhesive characteristics and VLA-4 expression of CD34(+) progenitors in G(0)/G(1) versus S+G(2)/M phases of the cell cycle.
Blood.
1998;92:842-848
22.
Habibian HK, Peters SO, Hsieh CC, et al.
The fluctuating phenotype of the lymphohematopoietic stem cell with cell cycle transit.
J Exp Med.
1998;188:393-398 23. Wiesmann A, Kim M, Georgelas A, et al. Modulation of hematopoietic stem/progenitor cell engraftment by transforming growth factor beta. Exp Hematol. 2000;28:128-139[Medline] [Order article via Infotrieve]. 24. Monette F, DeMello J. The relationship between stem cell seeding efficiency and position in cell cycle. Cell Tissue Kinet. 1979;12:161-175[Medline] [Order article via Infotrieve].
25.
van Os R, Dawes D, Mislow JMK, Witsell A, Mauch PM.
Host conditioning with 5-fluorouracil and kit-ligand to provide for long-term bone marrow engraftment.
Blood.
1997;89:2376-2383
26.
Molineux G, Migdalska A, Haley J, Evans GS, Dexter TM.
Total marrow failure induced by pegylated stem-cell factor administered before 5-fluorouracil.
Blood.
1994;83:3491-3499
27.
Fleming WH, Alpern EJ, Uchida N, Ikuta K, Weissman IL.
Steel factor influences the distribution and activity of murine hematopoietic stem cells in vivo.
Proc Natl Acad Sci U S A.
1993;90:3760-3764 28. de Haan G, Loeffler M, Nijhof W. Long-term recombinant human granulocyte colony-stimulating factor (rhG-CSF) treatment severely depresses murine marrow erythropoiesis without causing an anemia. Exp Hematol. 1992;20:600-604[Medline] [Order article via Infotrieve].
29.
de Haan G, Dontje B, Engel Ch, Loeffler M, Nijhof W.
Prophylactic pretreatment of mice with hematopoietic growth factors induces expansion of primitive cell compartments and results in protection against 5-fluorouracil-induced toxicity.
Blood.
1996;87:4581-4588
30.
Chervenick PA, Boggs DR, Marsh JC, Cartwright GE, Wintrobe MM.
Quantitative studies of blood and bone marrow neutrophils in normal mice.
Am J Physiol.
1968;215:353-360 31. Briganti G, Covelli V, Silini G, Srivastava PN. The distribution of erythropoietic bone marrow in the mouse. Acta Haematol. 1970;44:355-361[CrossRef][Medline] [Order article via Infotrieve].
32.
Ploemacher RE, van der Sluijs JP, Voerman JSA, Brons NHC.
An in vitro limiting-dilution assay of long-term repopulating hematopoietic stem cells in the mouse.
Blood.
1989;74:2755-2763
33.
Ploemacher RE, van der Sluijs JP, van Beurden AJ, Baert MRM, Lam Chan P.
Use of limiting-dilution type long-term marrow cultures in frequency analysis of marrow-repopulating and spleen colony-forming hematopoietic stem cells in the mouse.
Blood.
1991;78:2527-2533 34. Down JD, de Haan G, Dillingh JH, Dontje B, Nijhof W. Stem cell factor has contrasting effects in combination with 5-fluorouracil or total-body irradiation on frequencies of different hemopoietic cell subsets and engraftment of transplanted bone marrow. Radiat Res. 1997;147:680-685[CrossRef][Medline] [Order article via Infotrieve].
35.
de Wit R, Verweij J, Bontenbal M, et al.
Adverse effect on bone marrow protection of prechemotherapy granulocyte colony-stimulating factor support.
J Natl Cancer Inst.
1996;88:1393-1398
36.
van Os R, Robinson S, Sheridan T, Mislow JM, Dawes D, Mauch PM.
Granulocyte colony-stimulating factor enhances bone marrow stem cell damage caused by repeated administration of cytotoxic agents.
Blood.
1998;92:1950-1956
37.
Mardiney M, Malech HL.
Enhanced engraftment of hematopoietic progenitor cells in mice treated with granulocyte colony-stimulating factor before low-dose irradiation: implications for gene therapy.
Blood.
1996;87:4049-4056 38. Nikolic B, Sykes M. Mixed hematopoietic chimerism and transplantation tolerance. Immunol Res. 1997;16:217-228[Medline] [Order article via Infotrieve]. 39. Wekerle T, Sykes M. Mixed chimerism as an approach for the induction of transplantation tolerance. Transplantation. 1999;68:459-467[CrossRef][Medline] [Order article via Infotrieve].
40.
Childs R, Clave E, Contentin N, et al.
Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses.
Blood.
1999;94:3234-3241 41. Simpson E. The role of H-Y as a minor transplantation antigen. Immunol Today. 1982;3:97-106. 42. van Os R. Radiobiological studies on target cell populations in murine bone marrow transplantation recipients. Thesis Rijksuniversiteit Groningen: The Netherlands; 1994:1-186.
43.
van Os R, Sheridan TM, Robinson S, Drukteinis D, Ferrara JLM, Mauch PM.
Immunogenicity of Ly5 (CD45)-antigens hampers long-term engraftment following minimal conditioning in a murine bone marrow transplantation model.
Stem Cells.
2001;19:80-87 44. Wekerle T, Sayegh MH, Ito H, et al. Anti-CD154 or CTLA4lg obviates the need for thymic irradiation in a non-myeloablative conditioning regimen for the induction of mixed hematopoietic chimerism and tolerance. Transplantation. 1999;68:1348-1355[CrossRef][Medline] [Order article via Infotrieve].
45.
Wekerle T, Sayegh MH, Hill J, et al.
Extrathymic T cell deletion and allogeneic stem cell engraftment induced with costimulatory blockade is followed by central T cell tolerance.
J Exp Med.
1998;187:2037-2044
© 2002 by The American Society of Hematology.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  C. Barese, N. Pech, S. Dirscherl, J. L. Meyers, A. L. Sinn, M. C. Yoder, W. S. Goebel, and M. C. Dinauer Granulocyte Colony-Stimulating Factor Prior to Nonmyeloablative Irradiation Decreases Murine Host Hematopoietic Stem Cell Function and Increases Engraftment of Donor Marrow Cells Stem Cells, June 1, 2007; 25(6): 1578 - 1585. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||
Top
Abstract
Introduction
24, 
-irradiation unit (IBL 637, CIS Biointernational,
Gif-sur-Yvette Cedex, France).
